A Professional & Personal Networking Site for all People related to Cardiology
Harlan Krumholz, MD, cardiologist from Yale, discusses his letter to Circulation recommending that LDL be scrapped as a treatment target for statins and othe...
Great presentation, thanks!I totally agree with the criticism on treatment of such persons who don´t clearly benefit from treatment.For all that are at low to medium risk for MI or stroke it would be cheaper and much more benefit to modify the unhealthy habits. Advice (1) MOVE your body on a regular and frequent schedule (2) IMPROVE your eating habits: much more fresh fruit, vegetable and whole grain products; much less meat in general, and avoid fast food and high caloric ("soft") drinks (3) SLEEP enough and treat sleep related conditions (like sleep apnea, GERD or PLMS) (4) TREAT INFECTIONS of any kind appropriately (be it Helicobacter, chronic sinusitis or peridontitis). Drugs (as beneficial as they can be) are the pre-final step you should go. Risk of adverse effects, especially taking a multiple drugs is usually underestimated by patients as well as by many doctors. A lot of persons prefer drugs in place of life style changes - for convenience. But they should know that this is probably the less effective way to avoid desastrous medical events in their life. AND: we should clearly talk to them on their choices & the consequences.
I absolutely agree w Dr. Krumholz....the lipid theory of atherogenesis is invalid and the treatment guidelines are unsubstantiated now.....lowering VLDL & LDL does not decrease morbidity or mortality. Infection by CNPs (aka Nanobacteria) is the cause of CAD.....it meets all criteria for the endovascular research development of CAD/Heart Disease: They cause pathological calcification, their LPS endotoxin causes inflammation and secondary deposition of Beta-amyloid soft plaque....and CNPs denature VLDL & LDL as their foodstuff. Read more about the research and how to reverse CAD at: http://www.nanobiotech.us/nanobactx
Sign Upor Sign In
Or sign in with:
Niacin Therapy Lives for Another Day—Maybe?
Platelet Function Tests in Clinical Cardiology Unfulfilled Expectations
Extensive Xanthomas and Severe Subclinical Atherosclerosis in Homozygous Familial Hypercholesterolemia
Impact of Baseline Heart Failure Burden on Post-Implantable Cardioverter-Defibrillator Mortality Among Medicare Beneficiaries
Inside This Issue
© 2013 Cardiology Network.
Contact US |
Report an Issue |
Terms of Service
Please check your browser settings or contact your system administrator.